no doubt - but it's just a matter of time. the
Post# of 148280
the company is a different animal coming out of these challenges and ups & downs over the past couple of years - not just figuring out things like the MOA, which patients will benefit, etc. - but also by adding some rock stars like Recknor, Ray, etc., bolstering the CRO team, etc.
Not saying i'm glad to have gone through this year as an investor, but we're teed up for a monster 2022. I'd bet most of my investment portfolio on it (well, i am, literally)